Athersys (ATHX) 2.97 $ATHX
Ulcerative Colitis Therapeutics Pipeline Review 2015 - 66 Companies & 99 Drug Profiles
M2 - Tue Mar 03, 6:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/kwqzpf/ulcerative) has announced the addition of the "Ulcerative Colitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ulcerative Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ulcerative Colitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ajinomoto Pharmaceuticals Co., Ltd. - AlphaMab Co., Ltd - Altheus Therapeutics, Inc. - Am-Pharma B.V. - Amgen Inc. - Astellas Pharma Inc. - AstraZeneca PLC - Athersys, Inc. - Atlantic Healthcare plc - Avaxia Biologics, Inc. - Biocon Limited - BioLineRx, Ltd. - Bristol-Myers Squibb Company - Celgene Corporation - Cellceutix Corporation - Celltrion, Inc. - ChemoCentryx, Inc. - ChironWells GmbH - Cosmo Pharmaceuticals S.p.A - Dr. Falk Pharma GmbH - Drais Pharmaceuticals, Inc. - Effimune SAS - Emergent BioSolutions Inc. - Enceladus Pharmaceuticals BV - Epirus Biopharmaceuticals, Inc. - Euroscreen S.A. - Farmacija d.o.o. Tuzla - Flexion Therapeutics, Inc. - Galapagos NV - Genentech, Inc. For more information visit http://www.researchandmarkets.com/research/kwqzpf/ulcerative
FLXN: 25.38 (+2.23), EBS: 29.48 (+0.61), AMGN: 159.19 (+0.63), BMY: 65.67 (+3.75), AZN: 67.79 (-0.49), CCXI: 8.01 (+0.17), ATHX: 2.97 (+0.06), CELGZ: 3.24 (+0.01)
Athersys Up 12.7%, Shares Break Through Resistance (ATHX)
Comtex SmarTrend(R) - Mon Mar 02, 10:07AM CST
Athersys (NASDAQ:ATHX) is one of today's best performing low-priced stocks, up 12.7% to $2.92 on 5.4x average daily volume. Thus far today, Athersys has traded 4.5 million shares, vs. average volume of 835,000 shares per day. The stock has outperformed the Dow (12.7% to the Dow's 0.7%) and outperformed the S&P 500 (12.7% to the S&P's 0.4%) during today's trading.
ATHX: 2.97 (+0.06)
Athersys Lands Japan Partner for Stroke Therapy Ahead of Key Study Data
at The Street - Mon Mar 02, 8:38AM CST
Chugai decision to license MultiStem for Japan will look prescient or foolish depending on the stem cell therapy's performance in an ongoing phase II study of stroke patients.
ATHX: 2.97 (+0.06)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 8:15AM CST
CVM: 1.19 (+0.05), NBG: 1.43 (-0.07), NXPI: 99.47 (+0.74), LL: 35.64 (-5.14), LPI: 11.82 (-0.02), WBAI: 12.16 (+1.39), ANFI: 10.47 (+0.08), SYN: 2.38 (-0.03), GDP: 3.91 (unch), CYCC: 1.10 (-0.32), EGO: 5.21 (+0.02), CYTX: 1.14 (-0.06), TCPI: 2.82 (+0.11), OHRP: 10.72 (+0.37), ATHX: 2.97 (+0.06), ARCP: 10.10 (+0.02), FSL: 40.36 (-0.14), PCRX: 95.39 (+1.45), NAVI: 20.01 (-0.04), SMRT: 12.27 (+0.11)
Athersys up 20% on Chugai deal
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 7:48AM CST
ATHX: 2.97 (+0.06)
Athersys and Chugai Enter License Agreement and Collaboration to Develop MultiStem(R) Cell Therapy for Ischemic Stroke in Japan
GlobeNewswire - Mon Mar 02, 5:00AM CST
Athersys, Inc. (Nasdaq:ATHX) and Chugai Pharmaceutical Co., Ltd. (Tokyo Stock Exchange:4519) have announced a partnership and license agreement to exclusively develop and commercialize MultiStem cell therapy for ischemic stroke in Japan. Ischemic stroke represents a priority disease area in Japan, given the high healthcare burden of the condition and the expected increase in incidence associated with Japan's aging population.
ATHX: 2.97 (+0.06)
Athersys, Inc. (ATHX) in Focus: Stock Jumps 5.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 24, 8:18AM CST
Athersys, Inc. (ATHX) was a big mover last session, as the company saw its shares rise over 5% on the day.
ATHX: 2.97 (+0.06), AFFX: 11.83 (+0.09)
Athersys to Host Fourth Quarter and Annual Financial Results Call
GlobeNewswire - Tue Feb 17, 11:30AM CST
Athersys, Inc. (Nasdaq:ATHX) will release its 2014 fourth quarter and annual financial results at approximately 4:00 PM EDT on Thursday, March 12, 2015, and host a conference call shortly thereafter at 4:30 PM EDT to review the results. Gil Van Bokkelen, Chairman and Chief Executive Officer, and William (B.J.) Lehmann, President and Chief Operating Officer, will host the call as follows:
ATHX: 2.97 (+0.06)
NeoStem: The Levi Strauss Of Cell Therapy
Patrick Young - at Seeking Alpha - Thu Feb 12, 8:05AM CST
OCAT: 6.54 (-0.10), VCEL: 3.65 (+0.10), PSTI: 3.23 (+0.14), NBS: 4.03 (+0.04), GSK: 47.82 (+0.11), IMUC: 0.58 (unch), KITE: 63.19 (+1.72), BAX: 69.25 (-0.17), ONCE: 54.53 (-0.47), JUNO: 50.00 (+1.94), ATHX: 2.97 (+0.06), CUR: 3.67 (-0.01)
German Researchers Verify Positive, System-Wide Effect Of Pluristem's PLX Cell Therapy
Sharon di Stefano - Seeking Alpha - Wed Feb 11, 3:31PM CST
Pluristem Therapeutics Inc. (NASDAQ: PSTI ), maker of cell therapy for a wide variety of diseases, recently announced 12-month results from Phase I/II studies with its PLX-PAD off-the-shelf treatment for people who had undergone total hip...
PSTI: 3.23 (+0.14), CYTX: 1.14 (-0.06), STEM: 1.24 (-0.14), ATHX: 2.97 (+0.06), CUR: 3.67 (-0.01), CELG: 119.57 (+1.10)
Athersys to Present at 17th Annual BIO CEO & Investor Conference
GlobeNewswire - Tue Feb 03, 2:00PM CST
Athersys, Inc. (Nasdaq:ATHX) announced today that it will present at the 17 annual BIO CEO & Investor Conference to be held on February 9-10, 2015 in New York, NY, at The Waldorf Astoria New York.
ATHX: 2.97 (+0.06)
Convert Catalysts Into Profits: Sagient Research's Edward Stopke
Life Sciences Report - Seeking Alpha - Fri Jan 23, 7:51AM CST
The biotech sector is teeming with companies racing to bring the hot new drug or therapy to the marketplace. But realistically assessing the therapeutic potential of pipeline products is the healthy approach for selecting a winner. In this interview...
CPXX: 2.66 (-0.01), RPTP: 10.30 (+0.69), SRPT: 14.06 (+0.70), CLDX: 29.30 (+2.93), PTCT: 70.45 (+1.37), RMTI: 10.40 (+0.12), ATHX: 2.97 (+0.06), CUR: 3.67 (-0.01)
Athersys and Cell Therapy Catapult Announce Grant to Support Clinical Development of Stem Cell Therapy for Severe Acute Respiratory Condition
GlobeNewswire - Thu Jan 22, 6:00AM CST
Athersys Limited (an affiliate of Athersys, Inc.) (Nasdaq:ATHX) and the Cell Therapy Catapult, a not-for-profit centre, which is focused on the development of the United Kingdom cell therapy industry to increase the nation's health and wealth, are pleased to announce that Athersys Limited has been awarded a grant from Innovate UK, formerly the Technology Strategy Board, which will support a Phase 2a clinical study evaluating the administration of MultiStem cell therapy to acute respiratory distress syndrome (ARDS) patients.
ATHX: 2.97 (+0.06)
Hot Stock: Athersys, Shares Drop 7.2% (ATHX)
Comtex SmarTrend(R) - Wed Jan 21, 10:06AM CST
Athersys (NASDAQ:ATHX) is one of today's worst performing low-priced stocks, down 7.2% to $1.92 on 1.0x average daily volume. Athersys has traded 584,000 shares thus far today, vs. average volume of 570,000 shares per day. The stock has underperformed the Dow (-7.2% to the Dow's 0.4%) and underperformed the S&P 500 (-7.2% to the S&P's 0.7%) during today's trading.
ATHX: 2.97 (+0.06)
TiGenix: A Deeply Undervalued Stem Cell Company With Upcoming Catalysts
Logribel Biostocks - Seeking Alpha - Tue Jan 13, 8:59AM CST
TiGenix ( OTC:TGXSF ) -- listed on Euronext Brussels -- is a leading but little known Belgian cell therapy biotech with an advanced adipose-derived allogeneic stem cell product platform in various clinical stages. TiGenix also has a commercialized...
PFE: 34.64 (+0.08), OSIR: 17.80 (+0.28), GSK: 47.82 (+0.11), ATHX: 2.97 (+0.06)
Athersys to Present at Biotech Showcase 2015
GlobeNewswire - Thu Jan 08, 2:00PM CST
Athersys, Inc. (Nasdaq:ATHX) announced today that it will present at the Biotech Showcase(TM) 2015 to be held on January 12-14, 2015 in San Francisco, California, at the Parc 55 Wyndham San Francisco - Union Square.
ATHX: 2.97 (+0.06)
Nasdaq stocks posting largest volume increases
AP - Tue Jan 06, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
ATRI: 322.43 (-2.57), BRID: 7.75 (-0.09), ASBB: 19.81 (-0.49), WVFC: 11.89 (-0.22), CALI: 1.19 (-0.09), SFST: 16.88 (-0.12), WBB: 17.22 (-0.03), ANTH: 5.17 (+0.07), ANAT: 105.05 (+0.06), BTA: 11.47 (+0.09), FBMS: 14.76 (+0.18), ATHX: 2.97 (+0.06), STXS: 2.32 (+0.02), PZZI: 7.94 (+0.08)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Jan 06, 11:45AM CST
SD: 1.74 (unch), FRO: 2.60 (+0.02), EXXI: 4.48 (-0.29), HGG: 6.29 (+0.17), QADA: 21.25 (-0.17), CBMX: 2.04 (+0.05), CHOP: 0.87 (+0.02), CLDN: 19.63 (+0.83), MOC: 2.02 (unch), NDRM: 13.22 (+0.74), CALI: 1.19 (-0.09), GDP: 3.91 (unch), TNXP: 6.39 (+0.34), ICEL: 5.31 (unch), NERV: 5.20 (+0.06), CYTR: 3.15 (+0.03), BBLU: 1.04 (-0.06), ATHX: 2.97 (+0.06), PEIX: 9.33 (+0.17), PGN: 1.74 (-0.11)
Ulcerative Colitis Therapeutics Pipeline Review 2015 - 66 Companies & 99 Drug Profiles
M2 - Tue Mar 03, 6:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/kwqzpf/ulcerative) has announced the addition of the "Ulcerative Colitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ulcerative Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ulcerative Colitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ajinomoto Pharmaceuticals Co., Ltd. - AlphaMab Co., Ltd - Altheus Therapeutics, Inc. - Am-Pharma B.V. - Amgen Inc. - Astellas Pharma Inc. - AstraZeneca PLC - Athersys, Inc. - Atlantic Healthcare plc - Avaxia Biologics, Inc. - Biocon Limited - BioLineRx, Ltd. - Bristol-Myers Squibb Company - Celgene Corporation - Cellceutix Corporation - Celltrion, Inc. - ChemoCentryx, Inc. - ChironWells GmbH - Cosmo Pharmaceuticals S.p.A - Dr. Falk Pharma GmbH - Drais Pharmaceuticals, Inc. - Effimune SAS - Emergent BioSolutions Inc. - Enceladus Pharmaceuticals BV - Epirus Biopharmaceuticals, Inc. - Euroscreen S.A. - Farmacija d.o.o. Tuzla - Flexion Therapeutics, Inc. - Galapagos NV - Genentech, Inc. For more information visit http://www.researchandmarkets.com/research/kwqzpf/ulcerative
FLXN: 25.38 (+2.23), EBS: 29.48 (+0.61), AMGN: 159.19 (+0.63), BMY: 65.67 (+3.75), AZN: 67.79 (-0.49), CCXI: 8.01 (+0.17), ATHX: 2.97 (+0.06), CELGZ: 3.24 (+0.01)
Athersys Up 12.7%, Shares Break Through Resistance (ATHX)
Comtex SmarTrend(R) - Mon Mar 02, 10:07AM CST
Athersys (NASDAQ:ATHX) is one of today's best performing low-priced stocks, up 12.7% to $2.92 on 5.4x average daily volume. Thus far today, Athersys has traded 4.5 million shares, vs. average volume of 835,000 shares per day. The stock has outperformed the Dow (12.7% to the Dow's 0.7%) and outperformed the S&P 500 (12.7% to the S&P's 0.4%) during today's trading.
ATHX: 2.97 (+0.06)
Athersys Lands Japan Partner for Stroke Therapy Ahead of Key Study Data
at The Street - Mon Mar 02, 8:38AM CST
Chugai decision to license MultiStem for Japan will look prescient or foolish depending on the stem cell therapy's performance in an ongoing phase II study of stroke patients.
ATHX: 2.97 (+0.06)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 8:15AM CST
CVM: 1.19 (+0.05), NBG: 1.43 (-0.07), NXPI: 99.47 (+0.74), LL: 35.64 (-5.14), LPI: 11.82 (-0.02), WBAI: 12.16 (+1.39), ANFI: 10.47 (+0.08), SYN: 2.38 (-0.03), GDP: 3.91 (unch), CYCC: 1.10 (-0.32), EGO: 5.21 (+0.02), CYTX: 1.14 (-0.06), TCPI: 2.82 (+0.11), OHRP: 10.72 (+0.37), ATHX: 2.97 (+0.06), ARCP: 10.10 (+0.02), FSL: 40.36 (-0.14), PCRX: 95.39 (+1.45), NAVI: 20.01 (-0.04), SMRT: 12.27 (+0.11)
Athersys up 20% on Chugai deal
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 7:48AM CST
ATHX: 2.97 (+0.06)
Athersys and Chugai Enter License Agreement and Collaboration to Develop MultiStem(R) Cell Therapy for Ischemic Stroke in Japan
GlobeNewswire - Mon Mar 02, 5:00AM CST
Athersys, Inc. (Nasdaq:ATHX) and Chugai Pharmaceutical Co., Ltd. (Tokyo Stock Exchange:4519) have announced a partnership and license agreement to exclusively develop and commercialize MultiStem cell therapy for ischemic stroke in Japan. Ischemic stroke represents a priority disease area in Japan, given the high healthcare burden of the condition and the expected increase in incidence associated with Japan's aging population.
ATHX: 2.97 (+0.06)
Athersys, Inc. (ATHX) in Focus: Stock Jumps 5.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 24, 8:18AM CST
Athersys, Inc. (ATHX) was a big mover last session, as the company saw its shares rise over 5% on the day.
ATHX: 2.97 (+0.06), AFFX: 11.83 (+0.09)
Athersys to Host Fourth Quarter and Annual Financial Results Call
GlobeNewswire - Tue Feb 17, 11:30AM CST
Athersys, Inc. (Nasdaq:ATHX) will release its 2014 fourth quarter and annual financial results at approximately 4:00 PM EDT on Thursday, March 12, 2015, and host a conference call shortly thereafter at 4:30 PM EDT to review the results. Gil Van Bokkelen, Chairman and Chief Executive Officer, and William (B.J.) Lehmann, President and Chief Operating Officer, will host the call as follows:
ATHX: 2.97 (+0.06)
NeoStem: The Levi Strauss Of Cell Therapy
Patrick Young - at Seeking Alpha - Thu Feb 12, 8:05AM CST
OCAT: 6.54 (-0.10), VCEL: 3.65 (+0.10), PSTI: 3.23 (+0.14), NBS: 4.03 (+0.04), GSK: 47.82 (+0.11), IMUC: 0.58 (unch), KITE: 63.19 (+1.72), BAX: 69.25 (-0.17), ONCE: 54.53 (-0.47), JUNO: 50.00 (+1.94), ATHX: 2.97 (+0.06), CUR: 3.67 (-0.01)
German Researchers Verify Positive, System-Wide Effect Of Pluristem's PLX Cell Therapy
Sharon di Stefano - Seeking Alpha - Wed Feb 11, 3:31PM CST
Pluristem Therapeutics Inc. (NASDAQ: PSTI ), maker of cell therapy for a wide variety of diseases, recently announced 12-month results from Phase I/II studies with its PLX-PAD off-the-shelf treatment for people who had undergone total hip...
PSTI: 3.23 (+0.14), CYTX: 1.14 (-0.06), STEM: 1.24 (-0.14), ATHX: 2.97 (+0.06), CUR: 3.67 (-0.01), CELG: 119.57 (+1.10)
Athersys to Present at 17th Annual BIO CEO & Investor Conference
GlobeNewswire - Tue Feb 03, 2:00PM CST
Athersys, Inc. (Nasdaq:ATHX) announced today that it will present at the 17 annual BIO CEO & Investor Conference to be held on February 9-10, 2015 in New York, NY, at The Waldorf Astoria New York.
ATHX: 2.97 (+0.06)
Convert Catalysts Into Profits: Sagient Research's Edward Stopke
Life Sciences Report - Seeking Alpha - Fri Jan 23, 7:51AM CST
The biotech sector is teeming with companies racing to bring the hot new drug or therapy to the marketplace. But realistically assessing the therapeutic potential of pipeline products is the healthy approach for selecting a winner. In this interview...
CPXX: 2.66 (-0.01), RPTP: 10.30 (+0.69), SRPT: 14.06 (+0.70), CLDX: 29.30 (+2.93), PTCT: 70.45 (+1.37), RMTI: 10.40 (+0.12), ATHX: 2.97 (+0.06), CUR: 3.67 (-0.01)
Athersys and Cell Therapy Catapult Announce Grant to Support Clinical Development of Stem Cell Therapy for Severe Acute Respiratory Condition
GlobeNewswire - Thu Jan 22, 6:00AM CST
Athersys Limited (an affiliate of Athersys, Inc.) (Nasdaq:ATHX) and the Cell Therapy Catapult, a not-for-profit centre, which is focused on the development of the United Kingdom cell therapy industry to increase the nation's health and wealth, are pleased to announce that Athersys Limited has been awarded a grant from Innovate UK, formerly the Technology Strategy Board, which will support a Phase 2a clinical study evaluating the administration of MultiStem cell therapy to acute respiratory distress syndrome (ARDS) patients.
ATHX: 2.97 (+0.06)
Hot Stock: Athersys, Shares Drop 7.2% (ATHX)
Comtex SmarTrend(R) - Wed Jan 21, 10:06AM CST
Athersys (NASDAQ:ATHX) is one of today's worst performing low-priced stocks, down 7.2% to $1.92 on 1.0x average daily volume. Athersys has traded 584,000 shares thus far today, vs. average volume of 570,000 shares per day. The stock has underperformed the Dow (-7.2% to the Dow's 0.4%) and underperformed the S&P 500 (-7.2% to the S&P's 0.7%) during today's trading.
ATHX: 2.97 (+0.06)
TiGenix: A Deeply Undervalued Stem Cell Company With Upcoming Catalysts
Logribel Biostocks - Seeking Alpha - Tue Jan 13, 8:59AM CST
TiGenix ( OTC:TGXSF ) -- listed on Euronext Brussels -- is a leading but little known Belgian cell therapy biotech with an advanced adipose-derived allogeneic stem cell product platform in various clinical stages. TiGenix also has a commercialized...
PFE: 34.64 (+0.08), OSIR: 17.80 (+0.28), GSK: 47.82 (+0.11), ATHX: 2.97 (+0.06)
Athersys to Present at Biotech Showcase 2015
GlobeNewswire - Thu Jan 08, 2:00PM CST
Athersys, Inc. (Nasdaq:ATHX) announced today that it will present at the Biotech Showcase(TM) 2015 to be held on January 12-14, 2015 in San Francisco, California, at the Parc 55 Wyndham San Francisco - Union Square.
ATHX: 2.97 (+0.06)
Nasdaq stocks posting largest volume increases
AP - Tue Jan 06, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
ATRI: 322.43 (-2.57), BRID: 7.75 (-0.09), ASBB: 19.81 (-0.49), WVFC: 11.89 (-0.22), CALI: 1.19 (-0.09), SFST: 16.88 (-0.12), WBB: 17.22 (-0.03), ANTH: 5.17 (+0.07), ANAT: 105.05 (+0.06), BTA: 11.47 (+0.09), FBMS: 14.76 (+0.18), ATHX: 2.97 (+0.06), STXS: 2.32 (+0.02), PZZI: 7.94 (+0.08)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Jan 06, 11:45AM CST
SD: 1.74 (unch), FRO: 2.60 (+0.02), EXXI: 4.48 (-0.29), HGG: 6.29 (+0.17), QADA: 21.25 (-0.17), CBMX: 2.04 (+0.05), CHOP: 0.87 (+0.02), CLDN: 19.63 (+0.83), MOC: 2.02 (unch), NDRM: 13.22 (+0.74), CALI: 1.19 (-0.09), GDP: 3.91 (unch), TNXP: 6.39 (+0.34), ICEL: 5.31 (unch), NERV: 5.20 (+0.06), CYTR: 3.15 (+0.03), BBLU: 1.04 (-0.06), ATHX: 2.97 (+0.06), PEIX: 9.33 (+0.17), PGN: 1.74 (-0.11)
